Zubair Khalid

Virologist/Molecular Biologist | Veterinarian | Bioinformatician

Conventional & Molecular Virology • Vaccine Development • Computational Biology

Dr. Zubair Khalid is a veterinarian and virologist specializing in conventional and molecular virology, vaccine development, and computational biology. Dedicated to advancing animal health through innovative research and multi-omics approaches.

Dr. Zubair Khalid - Veterinarian, Virologist, and Vaccine Development Researcher specializing in Computational Biology, Multi-omics, Animal Health, and Infectious Disease Research

Category: Guides

Crispr Therapeutics

Crispr Therapeutics refers to the use of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and associated Cas proteins to treat human diseases by precisely editing the genome. This guide explains the core concepts, decision points, practical workflow, quality checks, common mistakes, and limits of CRISPR based therapies. It is intended for researchers, clinicians in training, bioinformaticians, and life science professionals who want a source bounded, actionable overview of how CRISPR moves from bench to potential bedside.

At a Glance

Aspect Key Point
Core Mechanism RNA guided Cas nuclease creates a double strand break, repaired by NHEJ or HDR.
Therapeutic Goal Correct disease causing mutations, knock out harmful genes, or insert therapeutic sequences.
Main Challenges Off target edits, delivery to target cells, immune response, and ethical oversight.
Workflow Target selection, guide design, delivery method choice, cell editing, validation, and quality control.
Key Resources NCBI Bookshelf for fundamentals, Galaxy Training for bioinformatics workflows, EMBL EBI for training data.

Core Concepts

CRISPR therapeutics rely on a programmable nuclease (most often Cas9 or Cas12a) that cuts DNA at a specific site defined by a short guide RNA. The cell repairs the break through either non homologous end joining (NHEJ) which often disrupts the gene, or homology directed repair (HDR) which can insert a precise edit using a donor template. The foundational biology is well described in the NCBI Bookshelf which provides authoritative references on DNA repair pathways and genome editing mechanisms.

In therapeutic contexts, researchers aim to correct mutations causing monogenic disorders (e.g., sickle cell disease, propionic acidemia) or to disrupt disease promoting genes (e.g., knockout of PCSK9 for cholesterol lowering). For example, a recent study used CRISPR Cas12a to edit the PCCA pseudoexon, showing potential for treating propionic acidemia Targeted gene editing of PCCA using CRISPR-Cas12a. Similarly, CRISPR Cas9 mediated disruption of anti ferroptotic genes has been explored to induce ferroptosis in cancer cells Ferroptosis induction via CRISPR/Cas9.

For bioinformatic support, the EMBL EBI Training offers resources on analyzing CRISPR sequencing data, while the Galaxy Training Network provides hands on workflows for guide RNA design and off target prediction.

Decision Criteria for Using CRISPR Therapeutics

Before initiating a CRISPR therapeutic project, consider these key decision points:

  1. Target Feasibility: Is the disease causing mutation amenable to NHEJ (disruption) or HDR (correction)? HDR is more efficient in dividing cells. For non dividing cells, NHEJ based approaches or base editors may be preferred.
  2. Off Target Risk: Use in silico tools to predict off target sites. Validate with targeted deep sequencing. A study on XRCC5 and XRCC6 knockdown showed enhanced HDR at the CHST6 locus, highlighting how modulating repair pathways can improve precision Knockdown of XRCC5 and XRCC6 using CRISPR/Cas9 enhances HDR.
  3. Delivery Method: Viral vectors (AAV, lentivirus) or lipid nanoparticles? Each has trade offs in cargo capacity, immunogenicity, and cell type tropism.
  4. Ethical and Regulatory: Somatic cell editing is more accepted than germline. Obtain appropriate approvals.
  5. Readouts: Define success as percentage of edited cells, functional correction, and absence of toxicity.

Practical Workflow or Implementation Steps

A typical CRISPR therapeutic project follows these steps:

  1. Define the genetic target. Use databases like ClinVar or NCBI Bookshelf to confirm the pathogenic variant.
  2. Design guide RNAs. Use tools such as those integrated in Galaxy Training Network to select guides with high on target score and minimal off targets.
  3. Select a Cas variant. Choose Cas9 (Streptococcus pyogenes) for NHEJ or Cas12a for certain applications. Consider high fidelity variants to reduce off target cutting.
  4. Prepare donor template (if HDR). For HDR, design a single stranded oligonucleotide or plasmid donor with homology arms.
  5. Deliver components into target cells. For ex vivo therapy (e.g., hematopoietic stem cells), use electroporation or viral transduction. For in vivo, use lipid nanoparticles or AAV.
  6. Edit cells and expand. Culture cells under appropriate conditions. Monitor for editing efficiency via PCR and Sanger sequencing.
  7. Validate edits. Use next generation sequencing of amplicons covering the target locus. The NCBI Sequence Read Archive can be used to deposit and share validation data.
  8. Perform off target analysis. Use unbiased methods (e.g., GUIDE seq, CIRCLE seq) or targeted sequencing of predicted off target sites. The Bioconductor project offers R packages for analyzing CRISPR screens and off target data.
  9. Functionally test the corrected cells. For example, measure protein expression or pathway activity. In the ferroptosis study, researchers assessed lipid peroxidation after CRISPR mediated knockout Ferroptosis induction via CRISPR/Cas9.
  10. Scale up for therapeutic use. Follow good manufacturing practices (GMP) if moving to clinical trials.

Quality Checks

  • Editing efficiency: Quantify the percentage of alleles with intended edits using targeted deep sequencing.
  • Off target events: Sequence top 10-20 predicted off target sites. If any are found, redesign guides or use high fidelity Cas.
  • Karyotype stability: Ensure no large chromosomal rearrangements or aneuploidy (especially relevant in stem cells).
  • Functional rescue: Confirm that the edit restores normal protein function or phenotype. For example, in the propionic acidemia study, they measured metabolite levels after PCCA correction Targeted gene editing of PCCA.
  • Purity and sterility: For therapeutic cell products, test for endotoxin, mycoplasma, and viability.

Common Mistakes

  • Ignoring off target effects: Even a single off target edit in a tumor suppressor gene can be dangerous. Always perform rigorous off target validation.
  • Assuming HDR efficiency is high: In most primary cells, HDR rates are low (1-5%). Optimize by using HDR enhancers (e.g., SCR7, RS 1) or by knocking out NHEJ factors, but be aware of potential toxicity.
  • Using a single guide RNA without backup: Guides can fail, test at least two to three guides per target.
  • Neglecting delivery optimization: In vivo delivery is the biggest hurdle. A guide that works in HEK293 cells may fail in hepatocytes. Pilot delivery in the relevant cell type.
  • Skipping quality control on guide RNA synthesis: Poor quality synthetic gRNA reduces editing efficiency. Verify by mass spectrometry or PAGE.
  • Misinterpreting indels as successful correction: NHEJ creates random insertions/deletions that often cause frameshifts. If you need a precise correction, ensure HDR occurred by sequencing.

Limits and Uncertainty

CRISPR therapeutics are powerful but have clear boundaries:

  • Delivery remains the primary bottleneck. Efficient and safe delivery to all target cells in an organ (e.g., liver, lung) is not yet routine. The NCBI Bookshelf discusses current vector limitations.
  • Off target effects cannot be completely eliminated, even with high fidelity Cas. The frequency may be very low but potential for oncogenic activation exists.
  • Editing in non dividing cells (e.g., neurons) is challenging for HDR. Base editing or prime editing offer alternatives but have their own limitations.
  • Immune responses to Cas proteins from bacterial origin can reduce efficacy or cause inflammation. Strategies include using humanized Cas or transient immunosuppression.
  • Ethical and regulatory frameworks vary by country. Germline editing is not yet clinically accepted due to safety and moral concerns.
  • Long term effects of edits are unknown. The microbiome cancer crosstalk study highlights that systemic therapies affecting one cell type may have unintended consequences in others Bidirectional microbiota cancer crosstalk. Until large scale animal and human trials follow for years, uncertainty remains.

Frequently Asked Questions

Q: Can CRISPR cure any genetic disease? A: Not yet. Only diseases where the mutation can be corrected or disrupted in a sufficient proportion of target cells are candidates. Delivery, cell type, and editing efficiency are limiting factors. The NCBI Bookshelf contains detailed reviews on current therapeutic applications.

Q: How long does a typical CRISPR therapeutic project take from design to validation? A: In a research setting, roughly 3 to 6 months for a single target using established cell lines. Primary cells or in vivo work can take 6 to 12 months. Clinical timelines are much longer due to regulatory steps.

Q: Is CRISPR therapy approved for any human disease? A: As of 2025, the FDA has approved Casgevy (exagamglogene autotemcel) for sickle cell disease and beta thalassemia, which uses CRISPR to modify hematopoietic stem cells ex vivo. Several other candidates are in trials.

Q: What bioinformatics tools should I use for guide design? A: Start with the Galaxy Training Network for workflows. For deeper analysis, use Bioconductor packages like CRISPRseek or GUIDEseq. The EMBL EBI Training also offers courses on CRISPR data analysis.

References and Further Reading

Related Articles